Vilin Bio Med accepts resignation of CFO Avula Hariprasad
Vilin Bio Med accepted the resignation of Avula Hariprasad as Chief Financial Officer effective June 11, 2026. Hariprasad stepped down due to pre-occupation and other engagements. The company disclosed the change pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

*this image is generated using AI for illustrative purposes only.
Vilin Bio Med has accepted the resignation of Avula Hariprasad from the position of Chief Financial Officer, effective June 11, 2026. Hariprasad stepped down due to pre-occupation and other commitments requiring his attention. The resignation was tendered with effect from the close of business hours on June 11, 2026.
The disclosure was made to the National Stock Exchange of India in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that there are no other material reasons for the resignation beyond those stated.
Key Management Change Details
The following table outlines the specifics of the managerial change:
| Particulars | Details |
|---|---|
| Name of the Director / KMP | Mr. Avula Hariprasad |
| Reason for Change | Resignation as the Chief Financial Officer of the Company with effect from closing of the business hours of June 11, 2026 |
| Date of Cessation | June 11, 2026 |
| Brief Profile | Not Applicable |
The resignation letter was submitted to the Board of Directors of Vilin Bio Med Limited. Hariprasad expressed gratitude to the Board and management for the support during his tenure and wished the company continued success.
Historical Stock Returns for Vilin Bio Med
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.57% | -3.39% | -9.35% | +136.18% | +71.85% | +64.91% |
Who will be appointed as the new CFO, and what is the timeline for the announcement?
How will the CFO transition impact Vilin Bio Med's financial strategy and upcoming reporting deadlines?
What are the potential market reactions to this sudden leadership change?


























